Neurology Clinical Trials Market Growth at 6.5% CAGR to Reach USD 10.36 Bn by 2032

Key Highlights

• Neurology Clinical Trials Market size was valued at USD 6.67 Bn in 2025.
• Revenue is expected to reach nearly USD 10.36 Bn by 2032.
• The market is projected to grow at a 6.5% CAGR from 2026 to 2032.
• Phase II clinical trials dominated with 38.7% of total revenue in 2025.
• Phase III is expected to grow fastest during the forecast period.
• Interventional studies led study design with 82.2% revenue share in 2025.
• Huntington’s disease is expected to grow fastest at 7.5%.
• North America dominated with 45% market share in 2025.
• Middle East & Africa is expected to grow fastest at 8.5%.
• A total of 8,305 CNS trials were conducted between 2005 and 2023.

Why This Matters Now

Neurology drug development is facing a trial-design problem as dementia, stroke, Parkinson’s disease and rare CNS disorders rise faster than therapeutic certainty. Pharma companies, CROs and academic medical centers now need trials that can recruit the right patients, manage long endpoints and produce credible evidence.

Neurology Clinical Trials Market growth from USD 6.67 Bn in 2025 to USD 10.36 Bn by 2032 shows that CNS research is becoming a larger capital-allocation priority. The challenge is execution, not interest.

Market Overview

Neurology clinical trials evaluate therapies, devices and interventions for nervous-system diseases. These studies cover cerebrovascular disease, Alzheimer’s disease and other dementias, migraine, epilepsy, tetanus, meningitis, Parkinson’s disease, multiple sclerosis and poliomyelitis.

MMR identifies rising neurological illness as a major contributor to global disease burden. The report also states that more than 1,000 neural system ailments are included in the broader neurological disease landscape.

Dementia is a key demand signal. Alzheimer Europe data cited by MMR estimated 1,589,170 dementia patients in Germany in 2019, rising to 2,749,190 by 2050. That means Germany’s dementia burden could increase from 2.91% of the population in 2019 to 4.45% in 2050, creating sustained trial demand.

Request Sample Report at : https://www.maximizemarketresearch.com/request-sample/171139/

Key Trends Driving Growth

The first growth driver is neurological disease prevalence among aging populations. Neurological diseases are a leading cause of death in the elderly, and dementia patients often carry one or more chronic conditions. This makes trial design more complex and increases demand for targeted CNS studies.

Product pipelines are also expanding. Major companies are developing treatments for epilepsy, migraine, Parkinson’s disease, depression and other CNS disorders. Pipeline density increases demand for trial sites, CRO support and patient recruitment.

Government support is another driver. MMR links growth to government funding in neurological disease research and approvals to perform neurology clinical studies. Stem cell-based therapeutics for nerve repair and regeneration are also being studied by research institutes, universities and businesses in Europe, the United States and Canada.

Risks remain material. CNS drugs and injections can cause side effects such as depersonalization, inability to sleep, increased blood pressure and nerve damage. Corticosteroid injections can cause skin discoloration, infections and allergic reactions, while high treatment cost can limit acceptance.

Segment Insights

• Dominant Phase Segment: Phase II. Phase II clinical trials dominated in 2025 with 38.7% of total revenue. MMR links this to rare neurological disorders and limited availability of specific treatments, which keeps many trials in Phase II or Phase III.
• Fastest-Growing Phase Segment: Phase III. Phase III is expected to grow fastest because these trials are expensive, involve larger participant groups and often require longer treatment periods.
• Dominant Study Design: Interventional. Interventional trials led with 82.2% revenue share in 2025. MMR states that drugs or biologics represented most studies, followed by behavioral, clinical procedure and device intervention studies.
• Fastest-Growing Indication: Huntington’s Disease. Huntington’s disease is expected to grow at 7.5% during the forecast period, supported by increased R&D investment and prevalence signals.
• Covered Patient Populations: Pediatric, Adult and Geriatric Patients. The visible page does not identify a leading patient-population segment.
• Covered Routes of Administration: Oral, Intravenous, Subcutaneous, Intrathecal and Transdermal. The visible page does not identify a leading route.
• Covered End Users: Hospitals, Research Institutes, CROs and Academic Medical Centers. Exact end-user shares are not disclosed.

Regional Growth Story

North America dominated the Neurology Clinical Trials Market with 45% share in 2025. The region benefits from treatment awareness, healthcare infrastructure, improved reimbursement policies and business partnerships between pharmaceutical companies and CROs.

The United States is expected to hold the largest regional share. MMR cites Alzheimer’s disease burden and CDC data showing that someone in the United States has a stroke every 40 seconds. Stroke also reduces mobility in more than half of stroke survivors aged 65 and older.

Europe remains important through dementia prevalence and CNS research activity. Germany’s dementia burden is a clear example, while the UK, France and other European countries are included in the report scope.

Middle East & Africa is expected to grow fastest at 8.5%. MMR links regional demand to neurological, psychiatric, developmental and substance-use disorders, along with conflict-linked mental health challenges in the Middle East and North Africa.

Competitive Landscape

The market includes pharmaceutical companies, CNS-focused biotechs, hospitals, CROs and research organizations. Key players include Supernus Pharmaceuticals, Adamas Pharmaceuticals, Eli Lilly and Company, Aurora Health Care, AbbVie, Medtronic, Zydus Group, Athira Pharma, Annovis Bio, Biogen, Merck & Co., IQVIA, Covance, Medpace, Charles River Laboratories, Syneos Health, AstraZeneca, GlaxoSmithKline, Teva Pharmaceutical Industries, Sanofi, Novartis and Eisai.

Competition is shaped by neuroscience pipeline depth, trial execution capability and disease-area specialization. Companies with approved CNS products and broad candidates can support stronger site networks and longer-term development programs.

Supernus is focused on central nervous system diseases, with approved treatments across epilepsy, migraine, ADHD and Parkinson’s disease-related conditions. Adamas’ GOCOVRI position in Parkinson’s disease shows how symptom-specific therapies can create trial and market momentum.

Request Sample Report at : https://www.maximizemarketresearch.com/request-sample/171139/

Recent Developments

• Supernus Pharmaceuticals launched new products on 25 October 2022. Its strategy centers on developing and commercializing CNS treatments, which strengthens its neurology portfolio and trial relevance.
• Supernus’ neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, Parkinson’s disease hypomobility, cervical dystonia, chronic sialorrhea and dyskinesia. This breadth supports competitive positioning across multiple CNS pathways.
• Adamas Pharmaceuticals published pooled Parkinson’s disease analyses on 29 March 2021. The publication supported GOCOVRI as an approved medicine for dyskinesia and OFF episodes in Parkinson’s disease patients receiving levodopa-based therapy.
• Medtronic obtained CE clearance for InterStim Micro and InterStim SureScan MRI leads in Europe. The clearance supports use in Europe and neuromodulation-related clinical pathways.
• Stem cell-based therapeutics for nerve repair and regeneration are being studied across Europe, the United States and Canada. This creates an emerging opportunity in regenerative neurology trials.

Strategic Implications

For pharma companies, neurology trials demand larger evidence discipline. Rare diseases, long outcomes and heterogeneous patients increase trial risk.

For CROs, CNS expertise is a differentiator. Sponsors need recruitment capability, neurological endpoint management and operational experience.

For hospitals and academic centers, trial participation can expand access to novel therapies. It also requires infrastructure and trained investigators.

For regulators and payers, evidence quality matters. Improved reimbursement-policy signals in North America support adoption, but the visible report does not disclose reimbursement values.

Future Outlook

The Neurology Clinical Trials Market is positioned for steady expansion as dementia, stroke, Parkinson’s disease, Huntington’s disease, epilepsy, nerve injury and CNS product pipelines increase trial demand. North America leads through infrastructure and partnerships, while Middle East & Africa shows the fastest visible regional growth signal.

Future leaders will combine CNS pipeline depth, patient recruitment strength and trial-design discipline, while laggards will lose ground where neurological complexity exposes weak evidence generation.

Related Reports

Global Polio Vaccines Market: https://www.maximizemarketresearch.com/market-report/global-polio-vaccines-market/25422/

global N95 Mask Market: https://www.maximizemarketresearch.com/market-report/global-n95-mask-market/105931/

Acne Treatment Market: https://www.maximizemarketresearch.com/market-report/acne-treatment-market/214013/

Analyst Perspective

“According to Komal Patil, Research Analyst at Maximize Market Research, ‘The Neurology Clinical Trials Market is projected to grow from USD 6.67 Bn in 2025 to nearly USD 10.36 Bn by 2032 at a 6.5% CAGR, supported by neurological disease prevalence, aging populations, CNS product pipelines, government research support and stem cell-based therapeutic studies. Phase II trials lead with 38.7% share, while Phase III shows the fastest phase growth signal. Organizations with strong CNS execution and recruitment capability will be better positioned.’”

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting company that provides reliable, data-focused, and practical business insights. The firm serves a wide range of industries, including healthcare, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. Through market forecasts, competitive analysis, strategic consulting, and industry impact assessments, MMR helps organizations understand changing market conditions, identify growth opportunities, and make informed business decisions for long-term success.

2nd Floor, Navale IT Park Phase 3

Pune Banglore Highway, Narhe

Pune, Maharashtra 411041, India

+91 9607365656

sales@maximizemarketresearch.com